Efficacy and safety of etrolizumab in treatment of moderate to severe ulcerative colitis: A systematic review and meta‐analysis

Our results show that etrolizumab is an effective and safe drug for the induction and maintenance of clinical remission in moderate to severe ulcerative colitis patients, as proved by histologic and endoscopic findings. Future randomized trials are still needed to compare etrolizumab to the other agents and further establish its value for the practice.